Sensus Healthcare, Inc. (NASDAQ:SRTS) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Sensus Healthcare, Inc. (NASDAQ:SRTS) have received an average recommendation of “Moderate Buy” from the six brokerages that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $5.8333.

Several brokerages have commented on SRTS. Lake Street Capital dropped their price target on shares of Sensus Healthcare from $4.50 to $4.00 and set a “buy” rating on the stock in a research note on Friday, August 14th. Citigroup restated a “buy” rating on shares of Sensus Healthcare in a report on Friday, May 8th. Wall Street Zen downgraded shares of Sensus Healthcare from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 9th. Alliance Global Partners reiterated a “buy” rating on shares of Sensus Healthcare in a research note on Monday, August 17th. Finally, Weiss Ratings cut shares of Sensus Healthcare from a “sell (d)” rating to a “sell (d-)” rating in a research report on Tuesday, August 18th.

Sensus Healthcare Stock Up 4.5%

Shares of SRTS opened at $3.52 on Monday. The company has a market cap of $57.94 million, a P/E ratio of -3.74 and a beta of 1.10. Sensus Healthcare has a fifty-two week low of $2.66 and a fifty-two week high of $5.49. The firm’s 50 day moving average price is $3.05 and its 200 day moving average price is $3.52.

Sensus Healthcare (NASDAQ:SRTS) last released its earnings results on Thursday, August 13th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.41). Sensus Healthcare had a negative return on equity of 21.57% and a negative net margin of 88.45%.The company had revenue of $2.29 million for the quarter, compared to analyst estimates of $4.60 million.

Insider Activity at Sensus Healthcare

In other Sensus Healthcare news, Director Eric Sachetta acquired 34,697 shares of the company’s stock in a transaction on Monday, August 24th. The shares were bought at an average cost of $3.25 per share, for a total transaction of $112,765.25. Following the completion of the purchase, the director owned 209,310 shares in the company, valued at $680,257.50. This trade represents a 19.87% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Over the last 90 days, insiders have acquired 55,330 shares of company stock valued at $179,446. Insiders own 10.20% of the company’s stock.

Institutional Trading of Sensus Healthcare

Several hedge funds have recently made changes to their positions in SRTS. Greenline Wealth Management LLC acquired a new stake in Sensus Healthcare in the fourth quarter valued at $513,000. Rothschild Wealth LLC acquired a new position in shares of Sensus Healthcare during the 4th quarter worth $500,000. North Star Investment Management Corp. purchased a new position in shares of Sensus Healthcare in the 1st quarter valued at about $500,000. Pacific Ridge Capital Partners LLC increased its holdings in shares of Sensus Healthcare by 21.8% in the 4th quarter. Pacific Ridge Capital Partners LLC now owns 698,634 shares of the company’s stock valued at $2,781,000 after purchasing an additional 125,245 shares in the last quarter. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Sensus Healthcare in the second quarter valued at about $303,000. Institutional investors and hedge funds own 25.30% of the company’s stock.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.